Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis

The article presents a case of using genetically engineered biopharmaceutical tocilizumab in a child with systemic juvenile idiopathic arthritis. On the initial stage, the treatment was characterized by resistance to high doses of glucocorticoids and cytostatic drugs. Successful termination of visce...

Full description

Saved in:
Bibliographic Details
Main Authors: Y. M. Spivakovskiy, Y. V. Chernenkov, A. Y. Spivakovskaya, O. V. Skupova, E. N. Shulgina
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2016-02-01
Series:Педиатрическая фармакология
Subjects:
Online Access:https://www.pedpharma.ru/jour/article/view/1371
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849695740012527616
author Y. M. Spivakovskiy
Y. V. Chernenkov
A. Y. Spivakovskaya
O. V. Skupova
E. N. Shulgina
author_facet Y. M. Spivakovskiy
Y. V. Chernenkov
A. Y. Spivakovskaya
O. V. Skupova
E. N. Shulgina
author_sort Y. M. Spivakovskiy
collection DOAJ
description The article presents a case of using genetically engineered biopharmaceutical tocilizumab in a child with systemic juvenile idiopathic arthritis. On the initial stage, the treatment was characterized by resistance to high doses of glucocorticoids and cytostatic drugs. Successful termination of visceral and articular manifestations of systemic juvenile idiopathic arthritis and normalization of laboratory indicators of disease activity in the setting of use of interleukin 6 receptor blocker were described. We observed stable improvement of the child’s condition during a year-long follow-up in the setting of the selected anti-inflammatory therapy pattern.
format Article
id doaj-art-03b722ec9a7b4e8aaa034de25b1d9514
institution DOAJ
issn 1727-5776
2500-3089
language Russian
publishDate 2016-02-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-03b722ec9a7b4e8aaa034de25b1d95142025-08-20T03:19:41ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892016-02-0112667267610.15690/pf.v12i6.14911363Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic ArthritisY. M. Spivakovskiy0Y. V. Chernenkov1A. Y. Spivakovskaya2O. V. Skupova3E. N. Shulgina4Razumovskiy Saratov State Medical University, Saratov, Russian FederationRazumovskiy Saratov State Medical University, Saratov, Russian FederationRazumovskiy Saratov State Medical University, Saratov, Russian FederationRazumovskiy Saratov State Medical University, Saratov, Russian FederationRazumovskiy Saratov State Medical University, Saratov, Russian FederationThe article presents a case of using genetically engineered biopharmaceutical tocilizumab in a child with systemic juvenile idiopathic arthritis. On the initial stage, the treatment was characterized by resistance to high doses of glucocorticoids and cytostatic drugs. Successful termination of visceral and articular manifestations of systemic juvenile idiopathic arthritis and normalization of laboratory indicators of disease activity in the setting of use of interleukin 6 receptor blocker were described. We observed stable improvement of the child’s condition during a year-long follow-up in the setting of the selected anti-inflammatory therapy pattern.https://www.pedpharma.ru/jour/article/view/1371juvenile idiopathic arthritissystemic variantgenetically engineered biopharmaceuticalstocilizumab
spellingShingle Y. M. Spivakovskiy
Y. V. Chernenkov
A. Y. Spivakovskaya
O. V. Skupova
E. N. Shulgina
Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
Педиатрическая фармакология
juvenile idiopathic arthritis
systemic variant
genetically engineered biopharmaceuticals
tocilizumab
title Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
title_full Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
title_fullStr Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
title_full_unstemmed Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
title_short Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
title_sort clinical case of tocilizumab use in a patient with systemic juvenile idiopathic arthritis
topic juvenile idiopathic arthritis
systemic variant
genetically engineered biopharmaceuticals
tocilizumab
url https://www.pedpharma.ru/jour/article/view/1371
work_keys_str_mv AT ymspivakovskiy clinicalcaseoftocilizumabuseinapatientwithsystemicjuvenileidiopathicarthritis
AT yvchernenkov clinicalcaseoftocilizumabuseinapatientwithsystemicjuvenileidiopathicarthritis
AT ayspivakovskaya clinicalcaseoftocilizumabuseinapatientwithsystemicjuvenileidiopathicarthritis
AT ovskupova clinicalcaseoftocilizumabuseinapatientwithsystemicjuvenileidiopathicarthritis
AT enshulgina clinicalcaseoftocilizumabuseinapatientwithsystemicjuvenileidiopathicarthritis